Although acute myocarditis has not been described as an adverse event in landmark trials of coronavirus disease 2019 (COVID-19) vaccines, it has been frequently reported as a rare complication in the real world.1–6 The prognosis of this self-limiting condition is generally good, but little is known about the long-term outcomes.2 This work aims to report a single-center experience giving new insights into this topic.
Features and follow-up of patients affected by noninflammatory myocarditis after coronavirus disease 2019 vaccination / Corradetti, Sara; Sclafani, Matteo; Mistrulli, Raffaella; Gallo, Giovanna; Pagannone, Erika; Di Girolamo, Marco; Autore, Camillo; Battistoni, Allegra; Volpe, Massimo. - In: JOURNAL OF CARDIOVASCULAR MEDICINE. - ISSN 1558-2027. - 24:1(2022), pp. 65-68. [10.2459/JCM.0000000000001385]
Features and follow-up of patients affected by noninflammatory myocarditis after coronavirus disease 2019 vaccination
Corradetti, Sara;Sclafani, Matteo;Mistrulli, Raffaella;Gallo, Giovanna;Pagannone, Erika;Di Girolamo, Marco;Autore, Camillo;Battistoni, Allegra
;Volpe, Massimo
2022
Abstract
Although acute myocarditis has not been described as an adverse event in landmark trials of coronavirus disease 2019 (COVID-19) vaccines, it has been frequently reported as a rare complication in the real world.1–6 The prognosis of this self-limiting condition is generally good, but little is known about the long-term outcomes.2 This work aims to report a single-center experience giving new insights into this topic.| File | Dimensione | Formato | |
|---|---|---|---|
|
Corradetti_Features-and-follow-up_2022.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
801.07 kB
Formato
Adobe PDF
|
801.07 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
